SSA
DAWN

Schonfeld Strategic Advisors’s Day One Biopharmaceuticals DAWN Stock Holding History

Schonfeld Strategic Advisors’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-300,102
Closed -$2.8M – 2317
2025
Q4 		$2.8M Buy
300,102
+276,782
+1,187% +$2.31M 0.01% 759
2025
Q3 		$164K Sell
23,320
-76,270
-77% -$525K ﹤0.01% 1976
2025
Q2 		$647K Buy
99,590
+34,065
+52% +$234K ﹤0.01% 1461
2025
Q1 		$520K Buy
+65,525
New +$706K ﹤0.01% 1565
2024
Q4 		– Sell
-47,380
Closed -$660K – 2084
2024
Q3 		$660K Sell
47,380
-197,577
-81% -$2.82M ﹤0.01% 1315
2024
Q2 		$3.38M Buy
244,957
+7,209
+3% +$105K 0.02% 686
2024
Q1 		$3.93M Buy
237,748
+58,814
+33% +$880K 0.03% 730
2023
Q4 		$2.61M Buy
178,934
+42,234
+31% +$512K 0.02% 711
2023
Q3 		$1.68M Buy
136,700
+21,182
+18% +$276K 0.01% 876
2023
Q2 		$1.38M Buy
115,518
+10,578
+10% +$138K 0.01% 874
2023
Q1 		$1.4M Sell
104,940
-10,560
-9% -$206K 0.01% 806
2022
Q4 		$2.49M Buy
115,500
+92,113
+394% +$1.89M 0.02% 736
2022
Q3 		$468K Sell
23,387
-16,913
-42% -$360K ﹤0.01% 1803
2022
Q2 		$722K Buy
+40,300
New +$416K 0.01% 1170

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Schonfeld Strategic Advisors's DAWN Position: Q1 2026 in Review

Schonfeld Strategic Advisors sold out of Day One Biopharmaceuticals (DAWN) in Q1 2026, closing a stake of 300,102 shares — an estimated $2.8M sold.

Schonfeld Strategic Advisors first reported a position in DAWN in Q2 2022 and held it in 14 quarters. The position peaked at $3.93M in Q1 2024. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Schonfeld Strategic Advisors reported no remaining Day One Biopharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 300,102 Day One Biopharmaceuticals shares in Q1 2026, an estimated $2.8M.
  • Schonfeld Strategic Advisors first reported a position in Day One Biopharmaceuticals in Q2 2022 and held it in 14 quarters.
  • Schonfeld Strategic Advisors's Day One Biopharmaceuticals position peaked at $3.93M in Q1 2024.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2026, filed 15 May 2026.